Recent Research Analysts’ Ratings Updates for Verastem (VSTM)

Verastem (NASDAQ: VSTM) recently received a number of ratings updates from brokerages and research firms:

• 10/16/2026 – Verastem had its “buy” rating reaffirmed by Benchmark.
• 10/16/2026 – Verastem had its price target raised by Mizuho from $13.00 to $14.00. They now have an “outperform” rating on the stock.
• 10/15/2026 – Verastem was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 10/15/2026 – Verastem had its “buy” rating reaffirmed by Alliance Global Partners.
• 10/15/2026 – Verastem had its “outperform” rating reaffirmed by Royal Bank Of Canada. They now have a $19.00 price target on the stock, up from $14.00.
• 10/15/2026 – Verastem had its price target raised by BTIG Research from $18.00 to $24.00. They now have a “buy” rating on the stock.
• 10/14/2026 – Verastem had its “buy” rating reaffirmed by Jefferies Financial Group. They now have a $13.00 price target on the stock, up from $11.00.
• 10/8/2026 – Verastem had its “buy” rating reaffirmed by Citigroup.
• 10/5/2026 – Verastem had its “buy” rating reaffirmed by BTIG Research. They now have a $18.00 price target on the stock.
• 10/5/2026 – Verastem had its “buy” rating reaffirmed by HC Wainwright. They now have a $18.00 price target on the stock.
• 9/28/2026 – Verastem had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 9/27/2026 – Verastem was upgraded by Wall Street Zen from “sell” to “hold”.
• 9/19/2026 – Verastem was downgraded by Wall Street Zen from “hold” to “sell”.
• 9/17/2026 – Verastem is now covered by Wolfe Research. They set an “outperform” rating on the stock.
• 9/11/2026 – Verastem had its “buy” rating reaffirmed by HC Wainwright. They now have a $18.00 price target on the stock.
• 9/11/2026 – Verastem had its “buy” rating reaffirmed by BTIG Research. They now have a $18.00 price target on the stock.
• 9/5/2026 – Verastem was upgraded by Wall Street Zen from “sell” to “hold”.
• 9/4/2026 – Verastem was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.

Verastem Trading Up 2.3%

Verastem stock traded up $0.23 during trading on Tuesday, hitting $9.81. The company had a trading volume of 861,955 shares, compared to its average volume of 2,566,495. Verastem, Inc. has a 1-year low of $3.43 and a 1-year high of $10.82. The company has a current ratio of 2.25, a quick ratio of 2.22 and a debt-to-equity ratio of 1.48. The company’s 50 day simple moving average is $8.21 and its 200-day simple moving average is $6.19. The stock has a market cap of $888.88 million, a price-to-earnings ratio of -3.69 and a beta of 0.45.

Verastem (NASDAQ:VSTM) last released its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.35) EPS for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.08. The company had revenue of $40.08 million for the quarter, compared to analysts’ expectations of $22.88 million. Verastem had a negative return on equity of 467.49% and a negative net margin of 231.59%. As a group, analysts expect that Verastem, Inc. will post -1.51 EPS for the current fiscal year.

Insiders Place Their Bets

In other Verastem news, CEO Dan Paterson sold 44,121 shares of the business’s stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $8.00, for a total transaction of $352,968.00. Following the sale, the chief executive officer directly owned 652,712 shares in the company, valued at $5,221,696. This represents a 6.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 46,742 shares of company stock valued at $373,920. Insiders own 1.94% of the company’s stock.

Verastem, operating as Verastem Oncology, is a biopharmaceutical company focused on developing and commercializing targeted therapies for cancer. The company’s research is centered on tumors driven by abnormalities in the RAS/MAPK signaling pathway, which can promote cancer-cell growth and resistance to treatment.

Verastem’s leading product candidates include avutometinib, an oral RAF/MEK clamp designed to inhibit signaling within the RAS/MAPK pathway, and defactinib, an oral focal adhesion kinase inhibitor.